Literature DB >> 17519642

Olanzapine therapy in anorexia nervosa: psychobiological effects.

Francesca Brambilla1, Cristina Segura Garcia, Secondo Fassino, Giovanni Abbate Daga, Angela Favaro, Paolo Santonastaso, Carla Ramaciotti, Emilia Bondi, Carmen Mellado, Renata Borriello, Palmiero Monteleone.   

Abstract

Dopamine impairments occur in anorexia nervosa. The aim of this study was to see whether treatment with the atypical dopamine antagonist antipsychotic olanzapine improves the disorder. Thirty anorexics, 18 restricted and 12 bingeing-purging, underwent a 3-month course of cognitive behavioral therapy, plus at random and double-blinded oral olanzapine (2.5 mg for 1 month, 5 mg for 2 months) in half and oral placebo in the other half of them. BMI, psychopathological aspects (eating disorder inventory, Hamilton Rating Scale, Buss-Durkee Rating Scale, Yale Brown Cornell for Eating Disorders Rating Scale, temperament-character inventory), and homovanillic acid blood concentrations for dopamine secretion, were monitored at baseline and then monthly during the trial. At the end of the trial BMI, total eating disorder inventory, total Yale Brown Cornell for Eating Disorders Rating Scale, Buss-Durkee Rating Scale, Hamilton Rating Scale scores and in olanzapine-treated patients the subitems of eating disorder inventory ineffectiveness and maturity fear, of Buss-Durkee Rating Scale direct aggressiveness, of temperament-characteristic inventory persistence had improved significantly. When stratified for anorexia nervosa subtype, BMI changes were significant among anorexia nervosa bingeing-purging patient, 'depression' (Hamilton Rating Scale) and 'direct aggressiveness' (Buss-Durkee Rating Scale) among anorexia nervosa bingeing-purging patients, 'persistence' (temprerament-characteristic inventory), among anorexics restricted patients, with a trend toward significance for obsessivity-compulsivity (Yale Brown Cornell for Eating Disorders Rating Scale). homovanilic acid blood levels increased significantly in the cognitive behavioral therapy+olanzapine group. No correlations were observed between homovanilic acid concentrations and psychopathological parameters. The pharmacological treatment can significantly improve specific aspects of anorexia nervosa.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519642     DOI: 10.1097/YIC.0b013e328080ca31

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  36 in total

1.  Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa.

Authors:  Mark L Norris; Wendy Spettigue; Annick Buchholz; Katherine A Henderson; Rebecca Gomez; Danijela Maras; Isabelle Gaboury; Andy Ni
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-21       Impact factor: 2.576

Review 2.  Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials.

Authors:  Timothy D Brewerton
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 3.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

4.  Anorexia nervosa in a 14-year-old second-generation Hispanic adolescent boy.

Authors:  Panchajanya Paul; Sunny Mehta; Barbara J Coffey
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05       Impact factor: 2.576

5.  Psychotropic medication use in anorexia nervosa between 1997 and 2009.

Authors:  Pouneh K Fazeli; Genevieve L Calder; Karen K Miller; Madhusmita Misra; Elizabeth A Lawson; Erinne Meenaghan; Hang Lee; David Herzog; Anne Klibanski
Journal:  Int J Eat Disord       Date:  2012-06-26       Impact factor: 4.861

Review 6.  Anorexia nervosa.

Authors:  Kathleen Kara Fitzpatrick; James Lock
Journal:  BMJ Clin Evid       Date:  2011-04-11

7.  Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.

Authors:  Vikas Duvvuri; Taya Cromley; Megan Klabunde; Kerri Boutelle; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-02-22       Impact factor: 4.861

8.  Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial.

Authors:  Evelyn Attia; Joanna E Steinglass; B Timothy Walsh; Yuanjia Wang; Peng Wu; Colleen Schreyer; Jennifer Wildes; Zeynep Yilmaz; Angela S Guarda; Allan S Kaplan; Marsha D Marcus
Journal:  Am J Psychiatry       Date:  2019-01-18       Impact factor: 18.112

Review 9.  Anorexia nervosa.

Authors:  James D Lock; Kathleen Kara Fitzpatrick
Journal:  BMJ Clin Evid       Date:  2009-03-10

10.  Catechol-O-methyltransferase genotype modifies executive functioning and prefrontal functional connectivity in women with anorexia nervosa.

Authors:  Angela Favaro; Maurizio Clementi; Renzo Manara; Romina Bosello; Monica Forzan; Alice Bruson; Elena Tenconi; Daniela Degortes; Francesca Titton; Francesco Di Salle; Paolo Santonastaso
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.